Gleevec News and Research

RSS

Gleevec is a drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Gleevec blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor. Also called imatinib mesylate and STI571.

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).

27 May 2009

Genetic signature may predict patient response to GIST therapy

Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.

15 May 2009

Discovery of genetic pattern that may predict response to Gleevec in GIST

22 Apr 2009

Therapeutic effect of imatinib improved with addition of chloroquine

The therapeutic effects of the blockbuster leukemia drug imatinib may be enhanced when given along with a drug that inhibits a cell process called autophagy, researchers from the Kimmel Cancer Center at Jefferson reported in the Journal of Clinical Investigation.

13 Apr 2009

Gleevec reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors

Data published online and in an upcoming print issue of The Lancet show that Gleevec (imatinib mesylate) tablets, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.

20 Mar 2009

FDA approves Gleevec (imatinib mesylate) to prevent gastrointestinal stromal tumor

The U.S. Food and Drug Administration has approved Gleevec (imatinib mesylate) for a new indication – keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor or GIST.

21 Dec 2008

When less is more: Brief inhibition of cancer target is effective and less toxic

New research shows that the delicate balance between maximum clinical impact and toxicity may not be quite as fragile as scientists had previously believed.

8 Dec 2008

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Oregon Health & Science University Knight Cancer Institute researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family.

8 Dec 2008

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Startling findings from a new CML (chronic myelogenous leukemia) patient survey were presented at a satellite meeting of the American Society of Hematology annual meeting, in San Francisco.

8 Dec 2008

Kinase inhibitors may offer new therapeutic approach for treatment of type 1 diabetes

Researchers at the University of California, San Francisco have reported that two common cancer drugs have been used to block and reverse type 1 diabetes in mice.

18 Nov 2008

Two common cancer drugs prevent, reverse type 1 diabetes

Two common cancer drugs have been shown to both prevent and reverse type 1 diabetes in a mouse model of the disease, according to research conducted at the University of California, San Francisco.

18 Nov 2008

Scientists sequence genome of a cancer patient

For the first time, scientists have decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots.

6 Nov 2008

Gleevec holds potential as first drug to successfully treat neurofibromatosis

Researchers at the Indiana University School of Medicine report that the anti-cancer drug Gleevec holds out promise to become the first effective treatment for neurofibromatosis, a genetic disease that has resisted treatments until now.

30 Oct 2008

Discovery of mechanism and possible drug treatment for growth of nerve tumors in neurofibromatosis

Researchers studying neurofibromatosis type 1 - a rare disease in which tumors grow within nerves - have found that the tumors are triggered by crosstalk between cells in the nerves and cells in the blood.

30 Oct 2008

Cancer requires support from immune system to develop, researchers report

Tumors that grow around nerves in a rare genetic disease need cooperation from cells from the immune system in order to grow, reports a team of scientists, including researchers from UT Southwestern Medical Center.

30 Oct 2008

Vitamin C supplements appear to undercut the effectiveness of cancer drugs

A new study by scientists in the United States has revealed that vitamin C may blunt the effectiveness of chemotherapy treatment.

1 Oct 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

Researcher develops method for early detection of leukemia relapse

Researchers at the Fred Hutchinson Cancer Research Center have developed a method that allows for the early detection of a common mechanism of resistance on drug treatment for chronic myeloid leukemia.

10 Jul 2008

Could Gleevec help stroke victims?

For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.

23 Jun 2008

MicroRNA play a significant role in some human cancers

A new study demonstrates that microRNAs can modulate the expression of well known tumor-specific oncogenic translocation proteins and may play a significant role in some human cancers. The research, published by Cell Press in the June issue of the journal Cancer Cell, is likely to lead to new strategies for treating some specific lymphomas and leukemias.

9 Jun 2008

Gleevec News and Research

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

Genetic signature may predict patient response to GIST therapy

Discovery of genetic pattern that may predict response to Gleevec in GIST

Therapeutic effect of imatinib improved with addition of chloroquine

Gleevec reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors

FDA approves Gleevec (imatinib mesylate) to prevent gastrointestinal stromal tumor

When less is more: Brief inhibition of cancer target is effective and less toxic

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Kinase inhibitors may offer new therapeutic approach for treatment of type 1 diabetes

Two common cancer drugs prevent, reverse type 1 diabetes

Scientists sequence genome of a cancer patient

Gleevec holds potential as first drug to successfully treat neurofibromatosis

Discovery of mechanism and possible drug treatment for growth of nerve tumors in neurofibromatosis

Cancer requires support from immune system to develop, researchers report

Vitamin C supplements appear to undercut the effectiveness of cancer drugs

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Researcher develops method for early detection of leukemia relapse

Could Gleevec help stroke victims?

MicroRNA play a significant role in some human cancers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News